Mayo Endoscopic Subscore at Week 24 Is a Predictor of Future Loss of Response to Vedolizumab in Patients with Ulcerative Colitis in Clinical Remission [0.03%]
维多珠单抗治疗临床缓解的溃疡性结肠炎患者的Mayo内镜亚评分在预测未来复发中的作用
Daisuke Saito,Minoru Matsuura,Hiromu Morikubo et al.
Daisuke Saito et al.
Introduction: Vedolizumab (VDZ) is a gut-selective integrin antagonist approved for the treatment of ulcerative colitis. While its efficacy and safety have been demonstrated in clinical trials, real-world data on long-ter...
Fecal Microbiota Transplantation for Inflammatory Bowel Disease: Where We Stand and What Is Next [0.03%]
炎症性肠病的粪菌移植：现状及未来展望
Dai Ishikawa,Xiaochen Zhang,Kei Nomura et al.
Dai Ishikawa et al.
Background: Fecal microbiota transplantation (FMT) is an emerging therapeutic strategy for inflammatory bowel disease (IBD). Every step of the FMT process, from donor recruitment and patient selection to pretreatment prot...
Comparative Efficacy of Mesalazine and Ozanimod following Induction Treatment in Mesalazine-Exposed Advanced Therapy-Naïve Adult Ulcerative Colitis Patients [0.03%]
美沙拉嗪和ozanimod治疗美沙拉嗪暴露的成人溃疡性结肠炎患者的疗效比较
Geert D&#x;Haens,Ekaterina Safroneeva,Laurent Peyrin-Biroulet et al.
Geert D&#x;Haens et al.
Introduction: Both mesalazine and ozanimod are oral treatment options for patients with moderately active ulcerative colitis (UC). Methods: ...
An Early Phase 2 Double-Blind, Placebo-Controlled Study of E6011, a Novel Anti-Fractalkine Antibody, in Patients with Crohn's Disease [0.03%]
E6011治疗克罗恩病患者的二期临床试验：一项针对新型抗 fractalkine单克隆抗体的双盲、安慰剂对照一期研究
Taku Kobayashi,Toshifumi Hibi,Mamoru Watanabe et al.
Taku Kobayashi et al.
Introduction: E6011 is a newly developed humanized monoclonal antibody that binds to and neutralizes fractalkine with high specificity and affinity. In a previous phase 1, open-label study, E6011 demonstrated good tolerab...
C-Reactive Protein Levels in Patients with Isolated Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis) and Coexisting H. pylori Infection and IBD: A Comparative Study [0.03%]
单纯炎症性肠病(CD和UC)及合并幽门螺杆菌感染患者的C-反应蛋白水平的比较研究
Abdullah D Alotaibi
Abdullah D Alotaibi
Introduction: The association with Helicobacter pylori infection and inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is conflicting, with the former studies reporting a protec...
Fecal Calprotectin Levels in Post-Metabolic Bariatric Surgery Patients: A Retrospective Study [0.03%]
代谢胃旁路手术后患者的粪便Cal保护蛋白水平：一项回顾性研究
Fenna M M Beeren,Britt Roosenboom,Marcel B W Spanier et al.
Fenna M M Beeren et al.
Introduction: Fecal calprotectin (FCP) is a key biomarker for gastrointestinal inflammation, aiding in differentiating irritable bowel syndrome from active inflammatory bowel disease (IBD). Metabolic bariatric surgeries (...
[This corrects the article DOI: 10.1159/000547076.]. © 2025 The Author(s). Published by S. Karger AG, Basel.
Published Erratum
Inflammatory intestinal diseases. 2025 Oct 20;10(1):305. DOI:10.1159/000548283 2025
[This corrects the article DOI: 10.1159/000546858.]. © 2025 The Author(s). Published by S. Karger AG, Basel.
Published Erratum
Inflammatory intestinal diseases. 2025 Oct 20;10(1):304. DOI:10.1159/000548136 2025
Evolution of Growth following Anti-Tumor Necrosis Factor-α Therapy in Paediatric Crohn's Disease: Data from the Swiss IBD Cohort Study [0.03%]
儿童克罗恩病抗肿瘤坏死因子-α治疗后生长发育的变化趋势：来自瑞士炎症性肠病队列研究的数据
Cléa Kunz,Alain Schoepfer,Christiane Sokollik et al.
Cléa Kunz et al.
Introduction: Up to 85% of pediatric patients affected by Crohn's disease experience growth failure. This study aims to elucidate the effects of anti-tumor necrosis factor (TNF) biologics on patient growth. ...
The Impact of a Specialized Condition Management Program on Emergency Department Visits in Patients with Inflammatory Bowel Disease [0.03%]
针对炎症性肠病患者的专门状况管理项目对急诊科就诊影响的研究
Raj Kirit Patel,Raechel Davis,Aurel Iuga et al.
Raj Kirit Patel et al.
Introduction: Inflammatory bowel disease (IBD) burdens patients and healthcare systems, often due to frequent emergency department (ED) visits. Comprehensive programs that connect members to providers with disease-specifi...